Chief Executive Officer
With 12+ years of experience in utilizing biophysical techniques to solve the relevant problems in life sciences, Chaitanya is a seasoned professional and bring successful experience of developing technologies for drug-target deconvolution and drug-target interaction measurements in intact biological systems from his tenure at Eli Lilly & Company. Chaitanya earned a Ph.D. from The Ohio State University, Columbus, OH, USA. Along with technical expertise Chaitanya also brings a solid experience of conceptualizing, developing and managing start-up and nascent organizations. Earlier he served as the Board of Director for 'Kshitiz Inc.' from 2004-2007. He also directly handled project management efforts of several internationally reputed non-profit organizations. These transferable managerial skills are playing a key role in shaping Shantani.
Chief Operations Officer
With 10+ years of experience in conducting cutting-edge life science research Yanping brings a strong experience of working in two leading economies of the world - China and USA. She worked on the forefront of the axonal transport research and holds claims of developing widely acclaimed live-cell chamber neurofilament capture techniques. Yanping completed her Bachelor's Degree from University of Science and Technology of China and Ph.D. from The Ohio State University, Columbus, OH, USA. Yanping's exceptional project management and operational skills are playing critical role in defining, executing and delivering company objectives.
With 5+ years of association with Shantani, Saba has contributed to the development of Shantani’s internal discovery programs and the establishment of novel chemical proteomics technology platforms. Her core understanding of company’s expertise in the field of proteomics, protein chemistry, and cell biology is helping her in managing and leading the current business development activities of Shantani. Saba has earned a degree in pharmaceutical chemistry from Devi Ahilya University, Indore. She is currently focused on expanding company’s services portfolio of Target Identification and Biotherapeutic Characterization Technologies.